AI in Predictive Toxicology: Reducing Risk in Drug Development

Drug-induced toxicity remains the leading cause of clinical-stage drug development failure and a persistent driver of the pharmaceutical industry's escalating development costs, while the traditional animal toxicology testing paradigm that anchors regulatory safety assessment suffers from well-documented cross-species translation limitations. This paper proposes an AI-Integrated Predictive Toxicology Framework (AIPTF) combining a molecular structure-activity and toxicophore recognition engine, a multi-organ toxicity prediction and mechanism-of-action module, and a cross-species translation and regulatory evidence synthesis gateway, evaluated across 26 pharmaceutical and biotechnology organisations (large pharmaceutical companies$\mathbf{n}=\mathbf{1 2}$, biotechnology firms$\mathbf{n} \boldsymbol{=} \mathbf{9}$, contract research organisations$\mathbf{n} \boldsymbol{=} \mathbf{5})$processing 1,840,000 compound toxicity and bioactivity records (1,288,000 training / 552,000 test, 70/30 stratified split) and 74,800 tested chemical compounds across 6 toxicity endpoint categories (hepatotoxicity, cardiotoxicity, nephrotoxicity, genotoxicity, developmental toxicity, and neurotoxicity) over a 38-month evaluation horizon. The AIPTF achieves a composite predictive toxicology effectiveness score of$\mathbf{r}=\mathbf{0. 9 3 4}$against expert-validated toxicological outcome benchmarks, outperforming ML-only toxicity prediction platforms$(\mathbf{r}=\mathbf{0. 7 7 1}; \mathbf{+ 2 1. 1} \%$[$(\mathbf{0. 9 3 4 - 0. 7 7 1}) / \mathbf{0. 7 7 1}])$, traditional QSAR modelling approaches$(\mathbf{r}=\mathbf{0. 5 9 6;}+\mathbf{5 6. 7 \%}[(\mathbf{0. 9 3 4 - 0. 5 9 6}) / \mathbf{0. 5 9 6}])$, and animal-testing-only assessment without computational prediction$(\mathbf{r}=\mathbf{0. 5 1 2;}+\mathbf{8 2. 4 \%} \quad[(\mathbf{0. 9 3 4 - 0. 5 1 2}) / \mathbf{0. 5 1 2}])$. Deployment outcomes: +52.4% early-stage toxicity detection accuracy, +44.8% mechanism-of-action identification precision, -38.6% late-stage clinical failure rate, +29.4% animal testing burden reduction, 93.2% regulatory submission acceptance rate, and +62.8% development cost avoidance for abandoned toxic candidates. Sub-domain performance: Molecular Toxicity Prediction$(\mathbf{r}=\mathbf{0. 9 5 8})$, Multi-Organ Toxicity Assessment (0.947), ADMET Property Prediction (0.929), and Cross-Species Translation (0.876). Novel chemical scaffold unpredictability degrades AIPTF accuracy to 0.847 (-9.3% [(0.934-0.847)/0.934]), and rare/idiosyncratic toxicity detection to 0.792 (-15.2% [(0.934-0.792)/0.934]), with deployed mitigation protocols for both conditions.

Hali tarjima qilinmagan